The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

What is a menopause health assessment? And how will it improve the health care women receive during this stage in their lives ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

A robotic device developed by University of Utah engineers allows eye surgeons to perform high-precision procedures on the retina, the fragile lining on the back of the eye that is less than a ...